Overview

Solriamfetol in Binge Eating Disorder

Status:
Not yet recruiting

Trial end date:
2023-03-30

Target enrollment:

Participant gender:

Summary

The goal of this project is to evaluate the efficacy and tolerability of the novel dopamine and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of binge eating disorder (BED).

Phase:

Phase 4

Details

Lead Sponsor:

Lindner Center of HOPE

Collaborator:

Jazz Pharmaceuticals